Merz Tops Valeant With $383M Bid For Obagi
German drugmaker Merz Pharma Group on Tuesday launched a $383.5 million acquisition offer for California-based cosmetics company Obagi Medical Products Inc., topping a $344 million proposal from Valeant Pharmaceuticals International Inc....To view the full article, register now.
Already a subscriber? Click here to view full article